Robuta

Targeting AA metabolism offers a promising approach for glioblastoma treatment, with potential targeted drugs showing clinical promise. However, the complexity...

Gliomas are the second most common primary brain tumors in adults. They are treated with combination therapies, including surgery, radiotherapy, and...

Glioblastoma Foundation's mission is to transform glioblastoma treatment & research. Learn how you can help us change this disease from being terminal to...

Background/Objectives: Glioblastoma (GBM) is the deadliest type of brain tumor and photodynamic therapy (PDT) is a promising treatment modality of GBM....

Mar 5, 2025 - Henry Scowcroft looks at a pioneering new clinical platform trial set to offer more options to UK glioblastoma patients and kick-start progress

Glioblastomas are highly malignant primary brain tumors with one of the worst survival rates among all human cancers. With a more profound understanding of the...

Recurrent glioblastoma (GBM) is a fatal, treatment-resistant, malignant brain tumor that causes numerous neurological complications.

Glioblastoma (GBM) is an aggressive brain cancer with a poor survival rate. Despite hundreds of clinical trials, there is no effective targeted therapy....

Nov 14, 2025 - https://doi.org/10.18632/oncotarget.28770 Hugo Jimenez, Denise Gibo, Sambad Sharma, Michael Pennison, Lance D. Miller, Minghui Wang, Kimberly Sheffield, Liyue...

The function of macroautophagy/autophagy during tumor initiation or in established tumors can be highly distinct and context-dependent. To investigate the role...

We evaluated the efficacy and safety of bevacizumab beyond progression (BBP) in Japanese patients with newly diagnosed glioblastoma and explored predictors of...

This trial looked at depatuxizumab mafodotin (Depatux-M, ABT-414) with or without temozolomide for glioblastoma that came back after treatment.

Viska Bio is developing a proprietary antibody-enzyme fusion protein to induce anti-tumor immune responses through targeted oxidative damage.

Apr 4, 2016 - A variety of drugs targeting monoamine receptors are routinely used in human pharmacology. We assessed the effect of these drugs on the viability of tumor&

Normal tissue toxicity limits the efficacy of current treatment modalities for glioblastoma multiforme (GBM). We evaluated the influence of cannabinoids on...

Systematic reporting may help answer whether JC virus seropositivity and certain disease modifying therapies confer higher risk for glioblastoma in patients...

Mass effect has demonstrated prognostic significance for glioblastoma, but is poorly quantified. Here we define and characterize a novel neuroimaging...

Jan 23, 2023 - Treatment for glioblastoma may involve surgery, radiation therapy, chemotherapy, or a combination of all three. Learn more here.

Dec 10, 2025 - Il glioblastoma è la forma di tumore cerebrale più diffusa e più aggressiva. Non ci sono ancora cure definitive ma le terapie permettono di gestirlo.

Glioblastoma is the most aggressive cancer among primary brain tumours. As with other cancers, the incidence of glioblastoma is increasing; despite modern...

Researchers have identified 10 tumor-specific potential drug targets for the brain tumor glioblastoma.

SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. by Anita C Bellail, Jeffrey J Olson, Chunhai Hao. Nature...

Jun 22, 2023 - Three research teams have been awarded a combined total of £18 million to break new ground in the way we understand brain tumours and how they develop.

A new study suggests that gabapentin, a widely used anti-seizure medication, may improve survival in patients with glioblastoma (GBM), the deadliest form of...

Glioblastoma (GBM) is the most common malignant primary brain cancer that, despite recent advances in the understanding of its pathogenesis, remains incurable....

Glioblastoma multiforme (GBM) remains one of the deadliest brain cancers, with survival measured in months despite surgery, radiation, and chemotherapy. But...

Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.

Rap1 is a Ras family GTPase with a well documented role in ERK/MAP kinase signaling and integrin activation. Stimulation of the G-protein-coupled receptor...

Il tumore che ha colpito la scrittrice inglese Sophie Kinsella è il più comune dei tumori maligni del cervello e in Italia colpisce circa 1.500 persone ogni...

HLA-E and HLA-F play an important role in GBM biology and could be used as diagnostic biomarkers, and in the case of HLA-E also as a prognostic biomarker.

Aug 11, 2025 - Join Us On the seventh annual Glioblastoma Awareness Day, July 16, 2025, we gather to amplify the voices, experiences, and urgent needs of everyone living with...

Glioblastoma multiforme (GBM) is a major aggressive primary brain tumor with dismal survival outcome and few therapeutic options. Although Temozolomide (TMZ)...

The development of nano-based tools for diagnosis enables a more precise prognosis and results. Inorganic, organic, or hybrid nanoparticles using nanomateria...

Oncogenic protein tyrosine phosphatases have long been viewed as drug targets of interest, and recently developed allosteric inhibitors of SH2...

A new study paints one of the most detailed pictures of human brain development to date, opening the door to new tests and therapies, including for brain...

Adding marizomib to standard temozolomide-based radiochemotherapy resulted in more toxicity, but did not improve OS or PFS in patients with newly diagnosed...

As the country mourns the death of Sen. John McCain from brain cancer, there is hope that patients in the future will benefit from new research.

The gene expression pattern of glioblastoma (GBM) is well documented but the expression profile of brain adjacent to tumor is not yet analysed. This may help...

Learn more about services at Mayo Clinic.

scientific article published on May 2001

By signing an agreement with Medosome Biotec By providing support for clinical trial treatment of GBM at the University of Florida By starting a collaborative...

Newco Trogenix Ltd. has emerged from incubation and raised £70 million (US$94.1 million) in a series A, as it prepares the ground for a U.S/U.K. clinical...

Background: Glioblastoma (GBM) is the most invasive brain tumors, and it is associated with high rates of recurrence and mortality. The purpose of this study...

Glioblastoma (GBM) is the most common malignant primary brain tumor, with a median survival rate of less than two years. Currently, there is no cure for GBM,...

A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes (neoantigens), with...